Showing posts with label surgery. Show all posts
Showing posts with label surgery. Show all posts

Sunday, March 3, 2013

Chemotherapy and/or radiotherapy in combination with surgery for ovarian carcinosarcoma.

Chemotherapy and/or radiotherapy in combination with surgery for ovarian carcinosarcoma.

2013 Feb

Source

Gynaecological Oncology Division, Department of Surgical Oncology, Tata Memorial Centre, Dr Ernest Borges Marg, Parel, Mumbai, India, 400012.

Abstract

BACKGROUND:

Ovarian carcinosarcoma, also known as malignant mixed Mullerian tumour, is a rare malignant gynaecological tumour constituting about 1% or less of all ovarian cancers. In over 80% of cases, there is extra-ovarian intra-abdominal spread at diagnosis. The primary treatment has traditionally been surgical cytoreduction followed by radiotherapy and chemotherapy or chemotherapy alone. Regimes have included cisplatin alone; a combination of doxorubicin, ifosfamide, dacarbazine, cyclophosphamide, taxol; and various other combinations. The effectiveness of these various regimens appears to be mixed. Therefore, there is a need to clarify if there is an optimum neoadjuvant or adjuvant therapy after surgical cytoreduction for this rare tumour. Also, it is important to address quality of life (QoL) issues related to treatment, particularly toxicity, as the overall prognosis appears to be poor.

OBJECTIVES:

To assess the effectiveness and safety of various adjuvant and neoadjuvant chemotherapy and radiotherapy options or chemotherapy alone in combination with surgery in the management of ovarian carcinosarcoma.

SEARCH METHODS:

We searched the Cochrane Gynaecological Cancer Group Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and EMBASE up to February 2012. We also searched registers of clinical trials, abstracts of scientific meetings, reference lists of review articles and contacted experts in the field.

SELECTION CRITERIA:

We searched for randomised controlled trials (RCTs) that compared neoadjuvant or adjuvant chemotherapy and radiotherapy, or chemotherapy alone, in women with ovarian carcinosarcoma (malignant mixed Mullerian sarcoma of the ovary). We also reviewed non-randomised studies (NRS) for discussion in the absence of RCTs.

DATA COLLECTION AND ANALYSIS:

Two review authors independently assessed whether potentially relevant studies met the inclusion criteria. No trials were found and therefore no data were analysed.

MAIN RESULTS:

The search strategy identified 297 unique references of which all were excluded.

AUTHORS' CONCLUSIONS:

We found no evidence to inform decisions about neoadjuvant and adjuvant chemotherapy and radiotherapy regimens, or chemotherapy alone, for women with ovarian carcinosarcoma. Ideally, an RCT that is multicentre or multinational, or well designed non-randomised studies that use multivariate analysis to adjust for baseline imbalances, are needed to compare treatment modalities and improve current knowledge. Further research in genetic and molecular signalling pathways might improve understanding of this tumour subtype.

Friday, February 8, 2013

New surgery helps prevent ovarian cancer


New surgery helps prevent ovarian cancer


KGW Staff
Posted on February 7, 2013 at 3:59 PM

PORTLAND, Oregon -- Doctors at a Portland hospital have joined some others across the nation and Canada in following a new recommendation aimed at preventing one of the deadliest forms of cancer in women.
“This is something so simple that could save a lot of lives,” said Dr. Nathalie Johnson, the Medical Director of the Legacy Cancer Institute. Johnson is recommending women who have tubal ligations or hysterectomies have their fallopian tubes removed.
"It’s because researchers have found the tubes attract cancer cells which can eventually encase the ovary," she said. "You could actually find a normal ovary wrapped in cancer and realize the cancer was starting in the fallopian tube and not the ovary."
The recommendation is supported by research on thousands of women. Legacy researcher Dr. Ann Smith-Shedev has studied the connection for more than a decade.
“We think this could cut the most common type of ovarian cancer by up to 70 percent,” Shedev said.
The Legacy Cancer Institute is the first program in Oregon to make the recommendation that women consider the fallopian tube removal if they’re scheduling a tubal ligation or hysterectomy.
“We’d like to raise awareness and hopefully it can become the standard here in Oregon and across the country,” said Johnson.


** I had several massive experimental surgeries in the early 1970's for lymphedema at Good Samaritan Hospital, which is now Legacy. My questions are, "is this really the answer?  Have you also warned your patients about the possibility of leg or abdominal lymphedema from such a surgery?"  Your peers in the 1960's at the Oregon Health Sciences University wrote a very interesting article about abdominal/leg lymphedema from an abdominal surgery. Pat**

Sunday, December 16, 2012

The molecular biology of epithelial ovarian cancer.


The molecular biology of epithelial ovarian cancer.


Dec 2012

Source

Institut Gustave-Roussy, département de médecine, comité pluridisciplinaire de gynécologie, 114, rue Édouard-Vaillant, 94800 Villejuif, France.

Abstract


Epithelial ovarian cancer frequently presents at an advanced stage where the cornerstone of management remains surgery and platinum-based chemotherapy. Unfortunately, despite sometimes dramatic initial responses, advanced ovarian cancer almost invariably relapses. Little progress has been made in the identification of effective targeted-therapies for ovarian cancer. The majority of clinical trials investigating novel agents have been negative and the only approved targeted-therapy is bevacizumab, for which reliable predictive biomarkers still elude us. Ovarian cancer is treated as a uniform disease. Yet, biological studies have highlighted the heterogeneity of this malignancy with marked differences in histology, oncogenesis, prognosis, chemo-responsiveness, and molecular profile. Recent high throughput molecular analyses have identified a huge number of genomic/phenotypic alterations. Broadly speaking, high grade serous carcinomas (type II) display significant genomic instability and numerous amplifications and losses; low grade (type I) tumors are genomically stable but display frequent mutations. Importantly, many of these genomic alterations relate to known oncogenes for which targeted-therapies are available or in development. There is today a real potential for personalized medicine in ovarian cancer. We will review the current literature regarding the molecular characterization of epithelial ovarian cancer and discuss the biological rationale for a number of targeted strategies. In order to translate these biological advances into meaningful clinical improvements for our patients, it is imperative to incorporate translational research in ovarian cancer trials, a number of strategies will be proposed such as the acquisition of quality tumor samples, including sequential pre- and post-treatment biopsies, the potential of liquid biopsies, and novel trial designs more adapted to the molecular era of ovarian cancer research.

Tuesday, November 6, 2012

What is ovarian cancer and how can you fight it?

What is ovarian cancer and how can you fight it?


According to a study conducted by the World Health Organisation, one in every 12 women in urban India will, potentially, suffer from cancer. 


The five main types of cancer that can affect a woman's organs are cervical, ovarian, uterine, vaginal and vulvar. Among these, breast cancer is a leading cause behind the maximum number of cancer-related female deaths in India, closely followed by ovarian cancer.
Ovarian cancer is more dangerous than any other cancers because the survival rate of a woman suffering from ovarian cancer is far lower than any other cancer that affects women, as it is difficult to detect in the early stages. Today, we take a look at this slow killer and tell you how you can prevent it. 

What is ovarian cancer? 

According to ovariancancer.org, 'Ovarian cancer is a growth of abnormal malignant cells that begins in the ovaries.'

Ovarian cancer can be of two types: Benign (non-cancerous) and malignant (cancerous).

The only difference between the two is that in its benign form, the tumors do notspread to the other parts of the body; whereas in its malignant form, the tumor spreads to other parts of the body through the bloodstream. 


What are its symptoms? 

Early stages may not show many symptoms, but as the cancer grows there may be symptoms like:-

Pain in the abdomen, pelvis or legs

Swollen abdomen

Nausea, diarrhea or constipation

Feeling tired all the time

Difficulty in eating 


Weight loss or weight gain

Fatigue

Pain during intercourse

Frequent urination

The above symptoms are very common and may be associated with normal health worries, but if the problem persists over a longer duration, take medical assistance quickly as negligence may prove fatal. 


Is ovarian cancer treatable? 

Ovarian cancer is treatable, if detected in the early stages. If diagnosed at the right time, medical treatment can prevent the tumor/s from spreading to different parts of the body.

Depending on the stages of the cancer, your doctor may suggest a combination of treatments. Mostly a surgery is carried out, followed by chemotherapy. The various treatments are as follows. 


Surgery 

A surgery is carried out, both to diagnose ovarian cancer and to treat it as well. Tissue is removed from the ovary to examine it. Once examined, the main goal of the surgeon is to remove the tumor completely. To prevent the spreading of the tumor, your doctor may remove ovaries and the surrounding tissues. A second surgery may also be carried out after all other treatments. 

Chemotherapy 

This treatment uses drugs to slow down the growth of cancer and reduce the chances of reoccurrence. 

Radiation therapy 

Women with ovarian cancer are mostly treated with external radiation. The treatment uses a high energy X-ray to kill all the cancer causing cells. 

Risks factors 

The fact is that ALL women, are at a risk of developing ovarian cancer, simply because they are women. Therefore all women's should check the signs and prevent it from happening. Besides this, some other risk factors are 

Family history 

According to the American Cancer Society, 10% of ovarian cancer can be hereditary. Having a family history of ovarian, breast or colorectal cancer increases the chances of ovarian cancer in women. The possibility of developing ovarian cancer is due to the mutations in BRCA1 or BRCA2 genes. The younger you are or the family member who got diagnosed with the disease, the higher are your chances of developing ovarian cancer. 

Post menopausal 

Most of the ovarian cancer cases have been diagnosed in women who have crossed the age of 55-60 or after a women has entered menopause. 

Overweight 

According to Dr. Sheetal, there is a high chance of developing ovarian cancer if you are obese. The American Cancer Society has also correlated a higher rate of ovarian cancer in obese women. 

Infertility 

Women who have never been pregnant or have used some sort of drugs to achieve pregnancy seem to have a higher risk of developing ovarian cancer. 

What can one do to prevent ovarian cancer? 

The appropriate medicine has still not been discovered, but here are a few tips to reduce one's risk of developing ovarian cancer. 

Oral contraception 

Consumption of birth control pills for more than 5 years can reduce the risk of developing ovarian cancer. The longer the birth controls pills are used, the lesser are the chances of developing ovarian cancer. However, you must consult your doctor before assuming that the pills you take will prevent ovarian cancer, especially if you take them regularly. 

Breastfeeding and pregnancy 

Bearing children before the age of 28 can reduce the risk of ovarian cancer. Breastfeeding may also decrease one's risk of developing ovarian cancer. 
Surgical prevention 

Women who are at a higher risk of developing ovarian cancer due to genetics or who are outside of their reproductive stages can opt for surgical preventions. The various surgical preventions such as tubal ligation and oophorectomy can greatly reduce the risk of developing ovarian cancer.Read more Personal Health, Diet & Fitness stories on www.healthmeup.com

Tuesday, September 25, 2012

Effect of radical cytoreductive surgery on omission and delay of chemotherapy for advanced-stageovarian cancer.


Effect of radical cytoreductive surgery on omission and delay of chemotherapy for advanced-stage ovarian cancer.


Oct 2012

Source

From the Departments of Obstetrics and Gynecology and Medicine, Columbia University College of Physicians and Surgeons, the Department of Epidemiology, Mailman School of Public Health, Columbia University, and the Herbert Irving Comprehensive Cancer Center, New York, New York.

Abstract


OBJECTIVE:

 Cytoreductive surgery is associated with extensive morbidity and may delay chemotherapy. We examined the associations among cytoreduction, perioperative complications, and delay or omission of chemotherapy.

METHODS:

 Women aged 65 years or older with stage III-IV ovarian cancer who were treated with surgery from 1991-2005 and recorded in the Surveillance, Epidemiology, and End Results-Medicare database were examined. We estimated the influence of extended cytoreduction as well as the occurrence of major perioperative complications on receipt and timing of chemotherapy and survival.

RESULTS:

 Among 3,991 patients, 479 (12%) failed to receive chemotherapy. Of those treated with chemotherapy, 2,527 (72%) initiated treatment within 6 weeks of surgery, 838 (24%) within 6-12 weeks, and 147 (4%) more than 12 weeks after surgery. In a multivariable model, older patients, those with comorbidities, mucinous tumors, and stage IV neoplasmswere more likely not to receive chemotherapy (P<.05). Extended cytoreduction and the occurrence of postoperative complications were not associated with omission of chemotherapy but were associated with chemotherapy delay. For every 14 patients who underwent one extended procedure and for every 13 who had two extended procedures, one patient had a delay in receipt of chemotherapy. For every 14 patients who had one complication and for every four who had two complications, one patient had a delay in receipt of chemotherapy. The occurrence of more than two perioperative complications (hazard ratio 1.31, 95% confidence interval [CI] 1.15-1.49) and initiation of chemotherapy more than 12 weeks after surgery (hazard ratio 1.32, 95% CI 1.07-1.64) were associated with decreased survival.

CONCLUSION:

 Extended cytoreductive surgery and perioperative complications significantly delay initiation but do not increase the chance of omission of chemotherapy for women with ovarian cancer.